Literature DB >> 9753033

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

J Bladé1, D Samson, D Reece, J Apperley, B Björkstrand, G Gahrton, M Gertz, S Giralt, S Jagannath, D Vesole.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9753033     DOI： 10.1046/j.1365-2141.1998.00930.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  362 in total

1.  Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Authors:  Heinz Ludwig; Elisabeth Rauch; Thomas Kuehr; Zdeněk Adam; Adalbert Weißmann; Hedwig Kasparu; Eva-Maria Autzinger; Daniel Heintel; Richard Greil; Wolfram Poenisch; Ercan Müldür; Niklas Zojer
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.

Authors:  Shaji K Kumar; Martha Q Lacy; Suzanne R Hayman; Keith Stewart; Francis K Buadi; Jacob Allred; Kristina Laumann; Philip R Greipp; John A Lust; Morie A Gertz; Steven R Zeldenrust; P Leif Bergsagel; Craig B Reeder; Thomas E Witzig; Rafael Fonseca; Stephen J Russell; Joseph R Mikhael; David Dingli; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

Review 3.  Bone marrow immunohistology of plasma cell neoplasms.

Authors:  A Wei; S Juneja
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

4.  Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.

Authors:  Sherry Mori; Brooke S Crawford; Julianna Vf Roddy; Gary Phillips; Pat Elder; Craig C Hofmeister; Yvonne Efebera; Don M Benson
Journal:  Hematol Oncol       Date:  2011-10-26       Impact factor: 5.271

5.  Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Authors:  Suzanne Lentzsch; Amy O'Sullivan; Ryan C Kennedy; Mohammad Abbas; Lijun Dai; Silvana Lalo Pregja; Steve Burt; Michael Boyiadzis; G David Roodman; Markus Y Mapara; Mounzer Agha; John Waas; Yongli Shuai; Daniel Normolle; Jeffrey A Zonder
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

6.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Authors:  Andrzej J Jakubowiak; Dominik Dytfeld; Kent A Griffith; Daniel Lebovic; David H Vesole; Sundar Jagannath; Ammar Al-Zoubi; Tara Anderson; Brian Nordgren; Kristen Detweiler-Short; Keith Stockerl-Goldstein; Asra Ahmed; Terri Jobkar; Diane E Durecki; Kathryn McDonnell; Melissa Mietzel; Daniel Couriel; Mark Kaminski; Ravi Vij
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

7.  Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents.

Authors:  Carlos Fernández de Larrea; Natalia Tovar; M Teresa Cibeira; Juan I Aróstegui; Laura Rosiñol; Montserrat Elena; Xavier Filella; Jordi Yagüe; Joan Bladé
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

8.  Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Authors:  Jatin J Shah; Edward A Stadtmauer; Rafat Abonour; Adam D Cohen; William I Bensinger; Cristina Gasparetto; Jonathan L Kaufman; Suzanne Lentzsch; Dan T Vogl; Christina L Gomes; Natalia Pascucci; David D Smith; Robert Z Orlowski; Brian G M Durie
Journal:  Blood       Date:  2015-09-17       Impact factor: 22.113

9.  Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.

Authors:  Christian Straka; Peter Liebisch; Hans Salwender; Burkhard Hennemann; Bernd Metzner; Stefan Knop; Sigrid Adler-Reichel; Christian Gerecke; Hannes Wandt; Martin Bentz; Tim Hendrik Bruemmendorf; Marcus Hentrich; Michael Pfreundschuh; Hans-Heinrich Wolf; Orhan Sezer; Ralf Bargou; Wolfram Jung; Lorenz Trümper; Bernd Hertenstein; Else Heidemann; Helga Bernhard; Nicola Lang; Norbert Frickhofen; Holger Hebart; Ralf Schmidmaier; Andreas Sandermann; Tobias Dechow; Albrecht Reichle; Brigitte Schnabel; Kerstin Schäfer-Eckart; Christian Langer; Martin Gramatzki; Axel Hinke; Bertold Emmerich; Hermann Einsele
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

10.  Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Authors:  Eva Rossmann; Anders Österborg; Eva Löfvenberg; Aniruddha Choudhury; Ulf Forssmann; Anja von Heydebreck; Andreas Schröder; Håkan Mellstedt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.